Table 1 Patient characteristics and univariable analysis of overall survival and overall recurrence
|  | Overall Survival (n = 1387) | Overall Recurrence | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Univariate Analysis | Multivariate Analysis | Univariate Analysis | Multivariate Analysis | |||||||
| Â | N | HR 95%CI | P value | HR 95%CI | P value | 5-yr CIR | SHR 95% CI | P value | SHR 95% CI | P value |
Primary tumor factor | ||||||||||
 Age at surgery, years | ||||||||||
   ≤ 65 | 971 | 1 |  | 1 |  | 19.9% | 1 |  |  |  |
  >65 | 416 | 1.169(1.010–1.352) | 0.036 | 1.112(0.898–1.376) | 0.330 | 21.0% | 1.063(0.826–1.368) | 0.633 |  |  |
Sex | ||||||||||
 Male | 772 | 1 |  |  |  | 21.7% | 1 |  |  |  |
 Female | 615 | 0.965(0.930–1.220) | 0.364 |  |  | 18.3% | 0.821(0.647–1.041) | 0.104 |  |  |
Smoking history | ||||||||||
 Never | 783 | 1 |  | 1 |  | 18.9% | 1 |  |  |  |
 Ever | 604 | 0.875(0.762–1.004) | 0.057 | 1.152(1.026–1.432) | 0.043 | 21.9% | 1.192(0.944–1.506) | 0.105 |  |  |
Pathologic stage | ||||||||||
 IA | 488 | 1 |  | 1 |  | 12.8% | 1 |  | 1 |  |
 IB | 899 | 1.217(1.106–1.461) | 0.001 | 1.318(1.071–1.621) | 0.010 | 24.2% | 2.048(1.547–2.710) | < 0.001 | 1.123(0.633–1.994) | 0.692 |
Surgery | ||||||||||
 Lobectomy | 1223 | 1 |  | 1 |  | 20.6% | 1 |  |  |  |
 Sublobar | 164 | 1.548(1.280–1.871) | < 0.001 | 1.196(0.914–1.564) | 0.192 | 20.7% | 1.053(0.590–1.274) | 0.468 |  |  |
Tumor histology | ||||||||||
 LUAD | 1028 | 1 |  |  |  | 19.1% | 1 |  |  |  |
 LUSC | 276 | 0.693(0.576–0.835) |  |  |  | 22.3% | 1.198(0.901–1.593) |  |  |  |
 LASC | 49 | 0.775(0.520–1.155) |  |  |  | 30.6% | 1.757(1.040–2.970) |  |  |  |
 Others | 34 | 1.081(0.700–1.669) | 0.001 |  |  | 20.6% | 1.115(0.525–2.369) | 0.145 |  |  |
Carcinoma type | ||||||||||
 LUAD | 1028 | 1 |  | 1 |  | 19.1% | 1 |  | 1 |  |
 Non-Non-LUAD | 359 | 0.735(0.623–0.867) | < 0.001 | 1.041(0.140–1.733) | 0.929 | 23.3% | 1.262(0.978–1.629) | 0.074 | 1.987(0.837–2.344) | 0.073 |
Predominant subtype of LUAD | ||||||||||
 MIA | 12 | 1 |  | 1 |  | 8.3% | 1 |  | 1 |  |
 Lepidic | 183 | 0.580(0.322–0.994) |  | 1.446(0.587–3.562) |  | 10.9% | 1.293(0.174–9.636) |  | 0.961(0.127–1.261) |  |
 Acinar | 178 | 1.084(0.603–1.950) |  | 1.119(0.615–2.035) |  | 20.7% | 2.603(0.357–8.974) |  | 1.833(0.247–3.623) |  |
 Papillary | 48 | 0.877(0.464–1.659) |  | 1.487(0.574–3.856) |  | 25.0% | 3.178(0.413–4.443) |  | 1.984(0.251–5.702) |  |
 Micropapillary | 2 | 0.478(0.107–2.137) |  | 0.807(0.800–6.262) |  | 50.0% | 10.576(0.661–16.154) |  | 9.424(0.559–10.928) |  |
 Solid | 24 | 1.501(0.746–3.023) | < 0.001 | 1.611(0.786–3.300) | < 0.001 | 33.4% | 4.911(0.614–9.268) | 0.070 | 2.979(0.368–4.104) | 0.030 |
EGFR status | ||||||||||
 Wild-type | 206 | 1 |  |  |  | 33.0% | 1 |  |  |  |
 Mutated | 277 | 1.032(0.849–1.255) | 0.753 |  |  | 27.0% | 0.789(0.568–1.095) | 0.157 |  |  |
LVI | ||||||||||
 Absent | 1336 | 1 |  | 1 |  | 19.0% | 1 |  | 1 |  |
 Present | 51 | 1.414(1.013–1.975) | 0.042 | 1.086(0.601–1.996) | 0.790 | 51.0% | 3.364(2.247–5.038) | < 0.001 | 1.586(1.339–2.936) | 0.037 |
VPI | ||||||||||
 Absent | 818 | 1 |  |  |  | 15.9% | 1 |  | 1 |  |
 Present | 569 | 0.899(0.783–1.033) | 0.132 |  |  | 26.4% | 1.779(1.408–2.248) | < 0.001 | 1.217(1.073–1.833) | 0.006 |
Adjuvant chemotherapy (stage IB) | 899 | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 No Chemotherapy | 555 | 1 |  |  |  | 13.5% | 1 |  | 1 |  |
 Chemotherapy | 344 | 1.038(0.870–1.238) | 0.678 |  |  | 41.3% | 3.925(2.952–5.219) | < 0.001 | 4.433(2.736–7.813) | < 0.001 |